Stella Lymberis, MD

05/21/2026

A message from our Executive Director, Paola Muggia for :

"Two years ago, I was diagnosed with Ovarian Cancer. I have an aggressive form of the disease, one that doesn't respond fully to standard treatment. In July 2025, my oncologist suggested participating in a Phase 1 clinical trial for a new targeted therapy known as an antibody drug conjugate. ADC's target specific parts of the cancer cell, sending a payload of medicine directly into the cell. This is a concept that was discussed almost 20 years ago and now the technology is here to make it a reality.

My response to date has been very good, and I'm living proof of why continued research is crucial to patients. Not all of us are made for standard treatments - we need other options to fight our disease.

Today, I'm thinking of the ovarian cancer patients I've known over the years, and the journeys they embarked on so that we could develop treatments to better fight this disease. Today is dedicated to them."

05/06/2026

Brain Cancer Awareness Month

Brain cancer treatments are evolving faster than ever, offering improved outcomes and new hope to patients. Join Perlmutter Cancer Center experts to hear the latest advances in treatment approaches and learn about the importance of personalized treatment plans and prioritizing overall well-being throughout one’s treatment journey. Participants will explore innovative surgical techniques, targeted radiation therapies, emerging systemic treatments—including chemotherapy, targeted therapy, and immunotherapy—and additional options available through clinical trials.

All are welcome. RSVP: https://bit.ly/4rkctOw

05/04/2026

05/04/2026

04/30/2026

Under the vision and leadership of President Dr. Antonios Gasparis HMS held the Inaugural Hippocratic Medical Symposium on April 19, 2026 with the theme: “Heart & Vascular Innovation: Emerging Science, Technologies and Future Therapies.”
https://hippocraticsymposium.org/

The event honored the legacy that spans from Hippocrates to pioneers such as Dr. George Papanicolaou, inventor of the Pap test, and Dr. Mary Kalopothakes, the first female Greek American physician.

• Eugenia Gianos, MD was recognized with the Dr. George Papanicolaou Award
• Roxana Mehran, MD was recognized with the Dr. Mary Kalopothakes Distinguished Female Physician Award
• Nicos Labropoulos, PhD was recognized with the Hippocrates Award

See the featured art by Costas Picadas which was on display and used for logo the heart sculpture was breathtaking.

The special delegation from the Global Doctors Hippocratic Institute, including Dr George Patoulis, and Konstantinos Panos enabled us to have the privilege of reciting the Hippocratic Oath in Ancient Greek and in English, committing as physicians to Hippocratic ideals and the as ethical legacy of do no harm.

https://hippocraticinstitute.com/en/

04/30/2026

Interesting I warned about the ethics of consent and privacy concerns of AI scribe technologies during my AI lecture AI for physicians Nuts and Bolts As a society we need to prioritize , and over and

Months after a lawsuit against a San Diego health system, another class action alleges two more California health systems used Abridge’s AI tool to record patient visits without consent.

04/29/2026

Learn about colon cancer prevention and treatment - Important since unfortunately incidence is rising among young adults prompting change of guidelines colonoscopy recommended starting at age 45. Have you had one? Don't delay!

04/28/2026

Improving outcomes in gynecologic oncology requires addressing access to care and timely initiation of treatment. Interestingly, even though overall treatment time OTT is a well known factor correlated with outcomes, study of time of treatment initiation has not been well studied with no current standard existing in guidelines.

Our study aimed to explore the demographic and clinical factors associated with delayed initiation of treatment for patients with cervical cancer treated with chemoradiation and brachytherapy and determine its impact on oncologic outcomes reviewing a 10 year database of patients I mostly treated with stage IB2 to IVA cervical cancer from 2009 to 2019.

Patients who initiated treatment within 8 weeks of diagnosis (early) were compared with those who initiated treatment after 8 weeks (delayed). We found that treatment initiation were associated with a decrement in .

In this cohort, public hospital patients were more likely to have a favorable stage and improved survival than those from the private hospital but also were more likely to experience treatment initiation delays. Referral patterns and delays related to diagnostic workup were the most common factors contributing to delays in care establishment with nearly 40% of patients with cervical cancer initiated treatment 8 weeks or later from the time of diagnosis.

System factors, such as transferring care for oncologic treatment or diagnostic workup, were the most common reasons for delays. Each incremental increase in treatment initiation of 10 days was associated with worse overall survival.



So grateful to Sarah S Lee, Kara Banson, Harika Koduru, Omar Ishaq and our team at Perlmutter Cancer Center at NYU Langone Peter Schiff, Dr. Oh, gyn oncs Dr. Curtin and Boyd. Full paper at: https://www.sciencedirect.com/science/article/pii/S1048891X25018961?via%3Dihub

04/17/2026

12/02/2025

Tonight Artificial Intelligence Healthcare Innovations December 2, 2025 All-star Panel on Healthcare AI. Live Zoom. Free Registration brought to you by Hellenic Medical Society at: https://hmsny.wildapricot.org/event-6420121